SciClone Announces First Patient Enrolled In Phase 2 Clinical Trial Using SCV-07 To Prevent Oral Mucositis
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of its first patient in its phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of SCV-07 for prevention of oral mucositis (OM) in patients receiving radio-chemotherapy for the treatment of head and neck cancer.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment